AUSTIN, Texas, March 4, 2025 /PRNewswire/ -- Superior HealthPlan ("Superior"), a leading managed care organization in Texas and a company of Centene Corporation (NYSE: CNC), is accepting applications for its annual grant program, open to community-based organizations and providers in Texas. The funding is targeted to address non-medical drivers of health, also known as social determinants of health, to meet the needs of low-income neighborhoods throughout the state.
"We are pleased to continue the Superior HealthPlan grant program that will support organizations and providers in Texas that make a difference in our communities," said Superior HealthPlan President and CEO, Mark Sanders. "Superior has provided these community grants for years and is looking forward to continuing this important program."
Since 2020, Superior has provided more than $740,000 in funding to community partners and providers through its grant program, which addresses barriers to health and wellness, such as access to food, economic stability, housing, education, and other critical needs.
In 2025, ten community-based organizations and ten providers will be selected to receive one of these grants, each receiving $10,000 in funding, for a total of $200,000. The funding will be made available in April.
To apply, organizations and providers must meet the following criteria:
Applications are due by March 31, 2025. To learn more and apply, visit SuperiorHealthPlan.com/grants.
About Superior HealthPlan
Founded in 1999, Superior HealthPlan is a managed care company that delivers quality healthcare throughout Texas. Committed to transforming the health of the communities we serve, one person at a time, Superior supports active local involvement in all 254 Texas counties with more than 3,300 employees throughout the state. Superior is a company of Centene Corporation, a leading healthcare enterprise that is committed to helping people live healthier lives. For more information visit www.SuperiorHealthPlan.com.
Last Trade: | US$27.08 |
Daily Change: | 0.91 3.48 |
Daily Volume: | 10,282,470 |
Market Cap: | US$13.300B |
July 29, 2025 July 25, 2025 April 25, 2025 February 24, 2025 |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREC4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load